Compare Equinix Inc (EQIX) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs ResMed Inc. — how do they compare? Equinix Inc trades at $1,018 (market cap $99.77B), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: Equinix Inc is far larger — about 3.1× ResMed Inc.'s market cap, and Equinix Inc pays the higher dividend (2.04%). Which is the better fit depends on your goals — on Pluang, investors hold Equinix Inc for 110 Days and ResMed Inc. for 51 Days on average.
| EQIX | RMD | |
|---|---|---|
Market Cap | $99.77B | $31.89B |
Volume | 480,425 | 618,314 |
Sector | Real Estate | Health |
52-Week High | $1.12K | $277.88 |
52-Week Low | $726.09 | $182.82 |
Typical Hold Time | 110 Days | 51 Days |
Enterprise Value | $120.90B | $31.24B |
Dividend Yield | 2.04% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,031.77, down 1.49% on the day, amid a bullish technical setup with support at $1,025 and resistance at $1,042. The company reported revenue growth to $9.22B in 2025 and a net income margin of 15.63%, though it missed EPS estimates in two of the last three quarters. Recent news highlights strong AI-driven demand for data centers, with Equinix planning $5B-$7B in annual investments to expand capacity.
Outlook remains positive given analyst consensus of a $1,250 price target and 75% buy ratings, but risks include high valuation multiples (P/E 65.07) and rising debt-to-asset ratio (47.13% in 2025). The stock offers growth exposure to AI infrastructure trends, yet investors should weigh capex intensity against earnings sustainability.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
